Characterization of jejunal enteroids in human obesity; a model for studying GLP-1 cells
February 9, 2026 / GLP-1 secretion / human jejunal enteroids / obesity and type 2 diabetes / enteroendocrine cell dysfunction / metabolic disease models
Human jejunal enteroids derived from obese individuals model enteroendocrine function in vitro, demonstrating preserved GLP-1 production but impaired glucose-stimulated GLP-1 secretion in obesity with type 2 diabetes, reflecting disease-associated endocrine dysfunction.
GLP-1s can’t solve New Jersey’s obesity crisis. What can? | Opinion
February 6, 2025 / metabolic syndrome / obesity treatment strategies / GLP-1 limitations / cardiometabolic health / insulin resistance prevention
GLP-1 therapies alone are insufficient to address obesity driven by metabolic syndrome; comprehensive metabolic health programs can reduce weight, medication dependence, and healthcare costs by targeting underlying insulin resistance and cardiometabolic risk factors.
Researchers urge focus on child obesity and gut health to reduce risk of diabetes
February 4, 2026 / childhood obesity / gut microbiota health / youth-onset type 2 diabetes / metabolic risk prevention / microbiome-based interventions
Researchers emphasize childhood obesity and gut microbiota as modifiable drivers of youth-onset type 2 diabetes, highlighting microbiome-informed risk stratification and early, personalized interventions to prevent metabolic dysfunction and insulin resistance.
Post-GLP-1 Problem: Assessing Fractyl Health’s Weight Loss Maintenance Data
February 4, 2026 / post-GLP-1 weight regain / obesity weight maintenance / gut-brain signaling / duodenal endoscopic therapy / metabolic set point regulation
Post-GLP-1 weight regain highlights unmet needs in obesity care; Fractyl Health’s duodenal endoscopic therapy showed reduced weight rebound, improved lipid markers, and decreased food cravings, supporting gut–brain signaling as a target for weight maintenance.
Researchers urge focus on child obesity and gut health to reduce risk of diabetes
February 4, 2026 / childhood obesity / gut microbiota / youth-onset type 2 diabetes / insulin resistance risk / microbiome-based prevention
Researchers highlight childhood obesity–related alterations in gut microbiota as early, modifiable drivers of insulin resistance and youth-onset type 2 diabetes, supporting microbiome-informed risk identification and personalized prevention strategies beginning early in life.
Data for Pfizer’s Monthly Injectable GLP-1 Drug Pave Way for Broad Phase 3 Plan in Obesity
February 3, 2026 / monthly GLP-1 injection / Pfizer obesity pipeline / Phase 3 obesity trials / long-acting incretin therapy / obesity drug development
Pfizer’s monthly injectable GLP-1 therapy demonstrated supportive mid-stage data, enabling a broad Phase 3 obesity program and positioning long-acting incretin-based monotherapy and combination regimens as central to next-generation pharmacologic obesity management.
Ultrasound detects abdominal fat linked to metabolic diseases
February 9, 2026 / visceral fat measurement / abdominal ultrasound / metabolic syndrome risk / prediabetes detection / body fat distribution
Abdominal ultrasound reliably quantifies visceral fat, closely matching MRI measurements, and identifies thresholds associated with prediabetes and metabolic syndrome, supporting its use as a practical, low-cost tool for metabolic risk stratification in clinical care.
Anti-Obesity Drugs Market to Reach US$195.99 Billion by 2036 as GLP-1 Therapies Drive a Structural Shift in Weight Management
February 6, 2026 / anti-obesity drug market / GLP-1 therapies / chronic obesity management / weight loss pharmacotherapy / metabolic disease treatment
The anti-obesity drug market is rapidly expanding as GLP-1 and multi-agonist therapies demonstrate durable weight-loss efficacy, reinforcing obesity’s recognition as a chronic disease and reshaping long-term pharmacologic management despite reimbursement and supply-chain challenges.
Obesity Is Not Just About Food: Bariatric Surgeon Explains the Role of Hormones & Metabolism
February 7, 2026 / obesity as a metabolic disease / bariatric surgery benefits / hormonal regulation of weight / insulin resistance obesity / metabolic health treatment
Experts emphasize obesity as a chronic hormonal and metabolic disease driven by dysregulated insulin, leptin, and ghrelin, where bariatric surgery improves weight and obesity-related comorbidities by restoring metabolic signaling rather than solely restricting caloric intake.
Eli Lilly Projects Record $80B-$83B Revenue for 2026 as Metabolic Franchise Decouples from Competition
February 6, 2026 / Eli Lilly GLP-1 / tirzepatide obesity treatment / metabolic disease therapeutics / GLP-1 GIP dual agonist / obesity diabetes market growth
Eli Lilly projects record 2026 revenue driven by high global demand for tirzepatide-based GLP-1/GIP therapies, reflecting obesity and diabetes treatment as cornerstone chronic metabolic care supported by expanded manufacturing, new delivery systems, and emerging oral agents.
New Drug Stops Weight Gain and Lowers Cholesterol by Targeting Nitric Oxide
January 29, 2026 / nitric oxide / obesity treatment / cholesterol reduction / fat metabolism / SCoR2 enzyme
Blocking the newly identified enzyme SCoR2, which removes nitric oxide from fat-regulating proteins, prevented weight gain and reduced cholesterol in mice—suggesting a novel therapeutic target for obesity, metabolic dysfunction, and fatty liver disease.
New Enzyme Discovery Could Lead to Combined Treatment for Obesity, Fatty Liver, and Heart Disease: Study Suggests
February 9, 2026 / SCoR2 enzyme / nitric oxide lipid metabolism / obesity drug target / fatty liver disease MASLD / cardiovascular metabolic risk
Researchers identified SCoR2, a novel enzyme regulating nitric oxide–dependent lipid metabolism; inhibiting SCoR2 reduced weight gain, LDL cholesterol, and fatty liver in mice, supporting a potential first-in-class therapy targeting obesity, MASLD, and cardiovascular disease.
Alaunos Therapeutics Pivots to Obesity Drug Development in Race Against Time
February 8, 2026 / non-hormonal obesity drugs / metabolic disease drug development / obesity treatment innovation / GLP-1 alternatives / biopharma pipeline shift
Alaunos Therapeutics has pivoted from oncology to developing non-hormonal obesity therapies, reflecting growing demand for alternative metabolic treatments, while facing near-term financial constraints that heighten the importance of advancing preclinical data toward IND-enabling studies.
Two in five adults walk around with fatty liver in Bengaluru, Chennai, Hyderabad: Study
February 9, 2026 / fatty liver disease MASLD / metabolic dysfunction liver disease / obesity and diabetes risk / visceral adiposity / population liver screening
A nationwide Indian study found metabolic dysfunction–associated steatotic liver disease affects nearly 40% of adults, driven primarily by obesity and diabetes, with significant regional variation and notable prevalence in lean individuals, underscoring widespread metabolic risk.
New tissue models could help researchers develop drugs for liver disease
February 3, 2025 / MASLD liver disease / liver tissue models / microphysiological systems / drug development liver disease / MASH treatment research
MIT researchers developed advanced liver microphysiological tissue models that replicate MASLD-related inflammation and insulin resistance, enabling improved preclinical drug testing and mechanistic insights into variable responses to therapies such as resmetirom.
High ultra-processed food diets linked to 47% higher cardiovascular disease risk
February 5, 2026 / ultra-processed foods / cardiovascular disease risk / metabolic syndrome inflammation / diet and heart health / preventable CVD risk
High intake of ultra-processed foods is associated with a 47% increased risk of cardiovascular disease, reinforcing links between UPFs, systemic inflammation, metabolic syndrome, and preventable heart attack and stroke risk.
Uncovering why a rare disease resulting in an abnormal loss of fat can also lead to diabetes
February 9, 2026 / lipodystrophy diabetes / adipose tissue dysfunction / insulin resistance mechanisms / metabolic disease research / fat cell inflammation
Researchers reveal that lipodystrophy-associated diabetes arises from adipocyte dysfunction, inflammation, and mitochondrial failure, showing that loss of healthy fat impairs lipid storage and hormonal signaling, driving insulin resistance and metabolic disease despite reduced adipose mass.
Partitioned polygenic scores show mechanistic heterogeneity in type 2 diabetes and hypertension comorbidity
February 9, 2026 / type 2 diabetes hypertension / polygenic risk scores / cardiometabolic comorbidity / genetic risk prediction / metabolic syndrome pathways
Partitioned polygenic risk scores reveal distinct genetic pathways linking type 2 diabetes and hypertension, improving prediction of comorbidity risk and highlighting heterogeneous mechanisms involving adiposity, beta-cell dysfunction, vascular biology, and metabolic syndrome for personalized prevention strategies.
Links between gut dysfunction and the eye may reveal therapeutic strategies for individuals with diabetic retinopathy
February 5, 2025 / diabetic retinopathy / gut microbiome metabolism / tryptophan absorption / incretin signaling / microbiome-based therapies
Restoring gut tryptophan metabolism corrects dysbiosis, strengthens gut barrier function, and protects retinal vasculature, preventing or reversing diabetic retinopathy and identifying microbiome-derived metabolites as novel therapeutic and biomarker targets in type 2 diabetes.